PCN43 THE COST OF TREATING GRADE 3/4 ADVERSE EVENTS RELATED TO FIRST-LINE THERAPY WITH BEVACIZUMAB PLUS CHEMOTHERAPY VERSUS CETUXIMAB PLUS CISPLATIN/VINORELBINE FOR PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN FRANCE
Oct 1, 2009, 00:00
10.1016/S1098-3015(10)74294-7
https://www.valueinhealthjournal.com/article/S1098-3015(10)74294-7/fulltext
Title :
PCN43 THE COST OF TREATING GRADE 3/4 ADVERSE EVENTS RELATED TO FIRST-LINE THERAPY WITH BEVACIZUMAB PLUS CHEMOTHERAPY VERSUS CETUXIMAB PLUS CISPLATIN/VINORELBINE FOR PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN FRANCE
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)74294-7&doi=10.1016/S1098-3015(10)74294-7
First page :
Section Title :
Open access? :
No
Section Order :
220